Rh D blood group conversion using transcription activator-like effector nucleases

Area of Science:

• Blood group research
• Gene editing technologies
• Transfusion medicine

Background:

• Group O D-negative red blood cells are universal donors, crucial for transfusion medicine.
• Current methods focus on converting A or B blood groups to O, but D-positive to D-negative conversion remains a challenge.
• The Rh D antigen, a key determinant in blood transfusions, is encoded by the RHD gene.

Purpose of the Study:

• To achieve the conversion of Rh D-positive erythroid progenitor cells into D-negative cells.
• To explore the potential of gene editing for creating universal donor blood cells.
• To overcome limitations in current blood group conversion strategies for transfusion compatibility.

Main Methods:

• Utilized transcription activator-like effector nucleases (TALENs) specifically targeting the RHD gene.
• Transfected erythroid progenitor cells with TALEN-encoding plasmids to induce RHD gene knockout.
• Differentiated RHD-knockout cells and assessed D antigen expression and agglutination properties.

Main Results:

• Successfully generated RHD-knockout erythroid progenitor cell clones.
• Differentiated cells from these clones showed no agglutination with anti-D reagents.
• Flow cytometry confirmed the absence of D antigen expression in the converted cells.

Conclusions:

• Programmable nuclease-induced gene editing can effectively convert Rh D-positive cells to D-negative.
• This method offers a novel approach for generating compatible donor cells in transfusion medicine.
• The study opens new possibilities for expanding the availability of universal donor blood products.